Name: 글로벌 시장 동향
SKU: CD1901
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 자궁경부암 진단 시장 규모는 2022년 81억 달러에 달했으며, 2030년까지 130억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 자궁경부암 진단 시장은 2023년부터 2030년까지 연평균 6.3%의 성장률을 기록할 것으로 예상됩니다.
자궁경부암 진단에는 다양한 검사와 기법이 사용되며, 자궁경부암 및 전암성 질환의 진단 및 모니터링에도 활용됩니다. 림프절 생검, 방광경 검사, 직장경 검사 또는 PET-CT(양전자 방출 단층촬영-컴퓨터 단층촬영)와 같은 영상 검사 등 추가적인 검사를 통해 자궁경부암의 병기를 확인합니다.
시장 동향
주요 업체들의 활발한 활동과 신제품 출시가 예측 기간 동안 전 세계 자궁경부암 진단 시장 성장을 견인할 것으로 예상됩니다.

여성에게 자궁경부암은 일반적으로 악성 종양입니다. 최근 몇 년 동안 발병률과 사망률이 증가하는 추세와 함께 발병률이 감소하는 경향이 뚜렷하게 나타나고 있습니다. 자궁경부암은 원인이 명확하고 조기 발견으로 완치될 수 있는 유일한 암입니다. 예를 들어, 뉴 호라이즌 헬스(New Horizon Health)에서 개발한 서비클리어(CerviClear) 검사는 세계 최초의 소변 기반 HPV 검출 및 자궁경부암 선별 검사입니다.
이 검사는 비침습적인 가정용 소변 자가 채취 방식으로 진행되며, 14가지 고위험 HPV 바이러스를 모두 검출하는 유일한 솔루션입니다. 이 제품은 이미 CE 마크를 획득하여 홍콩과 광둥-홍콩-마카오 대만구(Greater Bay Area)에 출시될 수 있습니다.
자궁경부암에 대한 소비자 인식이 높아짐에 따라 예측 기간 동안 전 세계 자궁경부암 진단 시장의 성장이 촉진될 것으로 예상됩니다.
자궁경부암은 예방 가능한 암 중 하나이며, 매년 인도 여성 약 7만 7천 명의 사망 원인이 되고 있습니다. 예를 들어, 2023년 4월, 암 인식, 예방 및 조기 발견을 촉진하는 비영리 단체인 암 인식 예방 및 조기 발견 신탁(CAPED)과 로슈 진단 인도(Roche Diagnostics India)는 양해각서(MoU)를 체결했습니다.
CAPED와의 협력은 로슈 진단 인도가 자궁경부암과 관련된 사회적 낙인을 없애고 자궁경부암 검진에 대한 인식을 높이기 위해 최근 추진한 여러 노력 중 하나입니다. 로슈 진단 인도는 국제적으로 자궁경부암 발병률을 줄이는 데 전념하고 있습니다.
진단 검사 비용이 높은 것이 예측 기간 동안 전 세계 자궁경부암 진단 시장 성장을 저해하는 요인으로 작용하고 있습니다.
자궁경부암 진단 검사 비용은 특정 검사, 지역, 의료 시설 환경 및 의료 시스템 등 여러 변수에 따라 달라질 수 있습니다. 팝 테스트(Pap test)는 지역과 의료진에 따라 20달러에서 100달러까지 다양합니다.
또한, HPV DNA 검사는 검사 기관과 사용되는 정확한 검사 기법에 따라 50달러에서 200달러 이상까지 비용이 발생합니다. 질확대경 검사 비용은 지역, 의료진, 검사 중 시행되는 추가 시술에 따라 200달러에서 800달러 사이입니다.
코로나19 영향 분석
코로나19 팬데믹은 자궁경부암 진단 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 의료 시스템에 부담이 가중되면서 자궁경부암 진단 서비스 이용이 제한되었습니다.
자궁경부 세포검사, HPV 검사, 질확대경 검사, 조직검사 등의 진단 검사 지연은 자원 부족, 의료기관 과부하, 코로나19 대응 활동으로의 인력 재배치 때문으로 분석됩니다.
2023년 현재, 코로나19 상황이 회복되면서 모든 환자들이 의료 시설을 이용할 수 있게 되었고, 이는 자궁경부암 진단 시장 성장을 견인하고 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 자궁경부암 진단 시장에 미치는 영향은 복잡하고 다면적입니다. 전투로 인해 사람들이 피난을 가거나, 교통이 마비되거나, 군사 검문소가 설치될 수 있습니다. 이러한 장애물은 의료 시설 접근을 제한하여 자궁경부암 진단 및 기타 의료 서비스를 신속하게 받기 어렵게 만들 수 있습니다.
또한, 분쟁 시에는 의료 자원과 노력이 외상 치료, 응급 대응 및 긴급 의료 지원에 집중됩니다. 이로 인해 자궁경부암 인식 개선 캠페인이나 검진 프로그램과 같은 공중 보건 활동이 줄어들어 검진율이 낮아지고 진단이 지연될 수 있습니다.
세분화 분석
세계 자궁경부암 진단 시장은 검사 유형, 연령대, 유통 채널, 최종 사용자 및 지역별로 세분화됩니다.
HPV DNA 검사 부문은 예측 기간 동안 시장에서 두 번째로 큰 비중을 차지할 것으로 예상됩니다.

HPV DNA 검사 부문은 2022년 자궁경부암 진단 시장에서 약 27.6%의 점유율로 두 번째로 높은 시장 점유율을 차지했습니다. HPV 검사는 세포 샘플을 분석하여 고위험 유형의 바이러스 감염 여부를 확인합니다. 이러한 감염이 장기간 지속되면 자궁경부 세포가 변형되어 자궁경부암으로 이어질 수 있습니다.
예를 들어, 2022년 9월, Mylab Discovery Solutions는 개인의 고위험 HPV 유형을 검사하기 위한 실시간 PCR 기반 스크리닝 도구인 "PathoDetect HPV Detection Test"를 출시했습니다. 'PathoDetect HPV Detection Test'는 규제 당국의 승인을 받은 검사로, 대부분의 자궁경부암을 유발하는 16형 및 18형과 같은 고위험 HPV 균주의 존재를 확인하고 구별합니다.

지리적 분석
주요 업체 간 협력 및 파트너십 증가, 자궁경부암 발병률 증가, 자궁경부암 진단 기술 발전이 북미 지역을 주도하고 있습니다.
북미는 자궁경부암 진단 시장에서 약 38.9%의 시장 점유율을 차지하며 시장을 선도할 것으로 예상됩니다. 2022년 국제 부인과 암 저널(International Journal of Gynecological Cancer)에 발표된 논문에 따르면, 시간 경과에 따른 추세를 분석한 결과, 진행성 자궁경부암 발병률이 매년 1.3%씩 증가하는 것으로 나타났습니다(p < 0.001). 자궁경부 선암의 증가율이 가장 높으며, 연평균 2.9%의 증가율을 보였습니다(p < 0.001).
인종, 지역, 연령을 종합적으로 분석한 결과, 미국 남부에 거주하는 40~44세 백인 여성의 진행성 자궁경부암 발병률이 매년 4.5%씩 가장 크게 증가하는 것으로 나타났습니다(p < 0.001). 경쟁 환경
주요 글로벌 시장 참여 기업으로는 QIAGEN, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics, Olympus, Cardinal Health, Siemens Healthcare, Hologic, Inc., Quest Diagnostics, Abbott Laboratories 등이 있습니다.
보고서 구매 이유

• 검사 유형, 연령대, 유통 채널 및 지역별 글로벌 자궁경부암 진단 시장 세분화 현황을 시각화하고 주요 기업 및 사업자를 파악할 수 있습니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 자궁경부암 진단 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

글로벌 자궁경부암 진단 시장 보고서는 약 61개의 표, 60개의 그림, 195페이지 분량으로 구성되어 있습니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Cervical Cancer Diagnostics Market size reached USD 8.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 13 billion by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.
A variety of tests and techniques are employed in the diagnosis and monitoring of cervical cancer and precancerous diseases as part of cervical cancer diagnostics. Additional procedures, such as lymph node biopsy, cystoscopy, proctoscopy or imaging tests like PET-CT (positron emission tomography-computed tomography), are carried out to ascertain the stage of cervical cancer.
Market Dynamics
Active Major Players and Cervical Cancer Diagnostic Product Launches are Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.
For women, cervical cancer is a typically malignant tumor. In recent years, there has been an apparent trend of rejuvenation along with an increase in morbidity and mortality. The only cancer that has a clear etiology and may be cured with early detection is cervical cancer. For instance, the CerviClear test, developed by New Horizon Health, is the world's first urine-based HPV detection and cervical cancer screening test.
It accomplishes non-invasive home-based urine self-sampling and is the only solution that completely covers all 14 high-risk HPV viruses. The product is eligible to be introduced in Hong Kong and the Greater Bay Area because it already possesses a CE Mark.
The Growing Awareness Among Consumers About Cervical Cancer is Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.
Cervical cancer is one of the most preventable cancers, it accounts for nearly 77,000 deaths among Indian women each year. For instance, in April 2023, the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India signed a Memorandum of Understanding (MoU).
The relationship with CAPED is one recent initiative by Roche Diagnostics India to remove the societal stigma associated with the disease and raise awareness about cervical cancer screening. Roche Diagnostics India is dedicated to reducing the incidence of cervical cancer internationally.
The High Cost of Diagnostic Tests is Hampering the Global Cervical Cancer Diagnostics Market Growth in the Forecast Period.
The price of cervical cancer diagnostic tests can vary depending on several variables, including the particular test, location, the environment for the medical facility and the healthcare system in existence. Pap tests can cost from $20 and $100, depending place and healthcare professionals.
In addition, HPV DNA tests cost from $50 to $200 or more, depending on the lab and the precise testing technique employed. A colposcopy operation might cost between $200 and $800, depending on the area, the healthcare professional and any extra procedures carried out during the examination.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the cervical cancer diagnostics market. The pandemic has put pressure on healthcare systems, which has restricted the availability of cervical cancer diagnostic services.
Delays in diagnostic testing, such as Pap smear tests, HPV tests, colposcopies and biopsies, have been attributed to a lack of resources, overburdened healthcare institutions and the redirection of workers to COVID-19 response operations.
As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities driving the cervical cancer diagnostics market.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the cervical cancer diagnostics market is complex and multifaceted. People may be displaced by the combat, transportation may be disrupted, and military checkpoints may be set up. These obstacles may limit access to medical facilities, making it difficult for people to get prompt cervical cancer diagnoses and other healthcare services.
In addition, healthcare resources and efforts were redirected during times of conflict to focus on trauma care, emergency response and urgent medical needs. This results in fewer public health measures, such as awareness campaigns and cervical cancer screening programs, which would lower screening rates and postpone diagnosis.
Segment Analysis
The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, end-user and region.
The HPV DNA Test Segment is Expected to Hold the 2nd Dominant Position in the Market Over the Forecast Period.
The HPV DNA test segment accounted for the 2nd highest market stake accounting for approximately 27.6% of the cervical cancer diagnostics market in 2022. An HPV test examines a sample of cells to see if they have a high-risk form of the virus. If such an infection persists for a long time, it may alter cervical cells and result in cervical cancer.
For instance, in September 2022, to test for high-risk HPV types in individuals, Mylab Discovery Solutions introduced the "PathoDetect HPV Detection Test," a real-time PCR-based screening tool. 'PathoDetect HPV Detection Test' is a regulatory authority-approved test that finds and distinguishes the presence of high-risk HPV strains, such as strains 16 and 18, which are responsible for the majority of cervical cancers.
Geographical Analysis
Increasing Collaborations and Partnerships Among the Key Players, Increasing Prevalence of Cervical Cancer and Advancement in Cervical Cancer Diagnostics Dominate the North American Region.
North America is expected to dominate the cervical cancer diagnostics market, accounting for around 38.9% of the market share. As per the article published in the International Journal of Gynecological Cancer in 2022, when examining the trends over time, it was discovered that the prevalence of cervical cancer in its remote stages increased annually at a rate of 1.3% (p 0.001). Cervical adenocarcinoma has the highest growth, with an average yearly percent change of 2.9% (p 0.001).
White women in the South aged 40–44 have the biggest increase in distant cervical cancer at a rate of 4.5% annually (p0.001), according to an intersecting analysis of race, location and age.
Competitive Landscape
The major global players in the market include QIAGEN Becton, Dickinson and Company F. Hoffmann-La Roche Ltd. Guided Therapeutics Olympus Cardinal Health Siemens Healthcare Hologic, Inc. Quest Diagnostics Abbott Laboratories among others.
Why Purchase the Report?
• To visualize the global cervical cancer diagnostics market segmentation based on the test type, age group, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Cervical Cancer Diagnostics Market Report Would Provide Approximately 61 Tables, 60 Figures and 195 Pages.
Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Age Group
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Incidence of Cervical Cancer
4.1.2. Restraints
4.1.2.1. High cost of diagnostic tests
4.1.3. Opportunity
4.1.3.1. Technological advances
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Test Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.1.2. Market Attractiveness Index, By Test Type
9.2. Pap Smear Test*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. HPV DNA Test
9.4. Coloscopy
9.5. EEC Test
9.6. Others
10. By Age Group
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.1.2. Market Attractiveness Index, By Age Group
10.2. Below 21*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. 21-29
10.4. 30-65
10.5. 65 and Above
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Hospital Pharmacies
11.4. E-Commerce
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. QIAGEN*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Becton, Dickinson and Company
14.3. F. Hoffmann-La Roche Ltd.
14.4. Guided Therapeutics
14.5. Olympus
14.6. Cardinal Health
14.7. Siemens Healthcare
14.8. Hologic, Inc.
14.9. Quest Diagnostics
14.10. Abbott Laboratories
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

QIAGEN, 4.	Key Developments, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics, Olympus, Cardinal Health, Siemens Healthcare, Hologic, Inc., Quest Diagnostics, Abbott Laboratories

표 목록 (Tables)

List of Tables

Table 1 Global Cervical Cancer Diagnostics Market Value, By Cancer Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Cervical Cancer Diagnostics Market Value, By Test Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Cervical Cancer Diagnostics Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Cervical Cancer Diagnostics Market Value, By Stage, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Cervical Cancer Diagnostics Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Cervical Cancer Diagnostics Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Cervical Cancer Diagnostics Market Value, By Cancer Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Cervical Cancer Diagnostics Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 9 Global Cervical Cancer Diagnostics Market Value, By Test Type, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Cervical Cancer Diagnostics Market Value, By Test Type, 2021-2030 (US$ Million)

Table 11 Global Cervical Cancer Diagnostics Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Cervical Cancer Diagnostics Market Value, By Age Group, 2021-2030 (US$ Million)

Table 13 Global Cervical Cancer Diagnostics Market Value, By Stage, 2022, 2026 & 2030 (US$ Million)

Table 14 Global Cervical Cancer Diagnostics Market Value, By Stage, 2021-2030 (US$ Million)

Table 15 Global Cervical Cancer Diagnostics Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 16 Global Cervical Cancer Diagnostics Market Value, By End User, 2021-2030 (US$ Million)

Table 17 Global Cervical Cancer Diagnostics Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 18 Global Cervical Cancer Diagnostics Market Value, By Region, 2021-2030 (US$ Million)

Table 19 North America Cervical Cancer Diagnostics Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 20 North America Cervical Cancer Diagnostics Market Value, By Test Type, 2021-2030 (US$ Million)

Table 21 North America Cervical Cancer Diagnostics Market Value, By Age Group, 2021-2030 (US$ Million)

Table 22 North America Cervical Cancer Diagnostics Market Value, By Stage, 2021-2030 (US$ Million)

Table 23 North America Cervical Cancer Diagnostics Market Value, By End User, 2021-2030 (US$ Million)

Table 24 North America Cervical Cancer Diagnostics Market Value, By Country, 2021-2030 (US$ Million)

Table 25 South America Cervical Cancer Diagnostics Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 26 South America Cervical Cancer Diagnostics Market Value, By Test Type, 2021-2030 (US$ Million)

Table 27 South America Cervical Cancer Diagnostics Market Value, By Age Group, 2021-2030 (US$ Million)

Table 28 South America Cervical Cancer Diagnostics Market Value, By Stage, 2021-2030 (US$ Million)

Table 29 South America Cervical Cancer Diagnostics Market Value, By End User, 2021-2030 (US$ Million)

Table 30 South America Cervical Cancer Diagnostics Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Europe Cervical Cancer Diagnostics Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 32 Europe Cervical Cancer Diagnostics Market Value, By Test Type, 2021-2030 (US$ Million)

Table 33 Europe Cervical Cancer Diagnostics Market Value, By Age Group, 2021-2030 (US$ Million)

Table 34 Europe Cervical Cancer Diagnostics Market Value, By Stage, 2021-2030 (US$ Million)

Table 35 Europe Cervical Cancer Diagnostics Market Value, By End User, 2021-2030 (US$ Million)

Table 36 Europe Cervical Cancer Diagnostics Market Value, By Country, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Cervical Cancer Diagnostics Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Cervical Cancer Diagnostics Market Value, By Test Type, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Cervical Cancer Diagnostics Market Value, By Age Group, 2021-2030 (US$ Million)

Table 40 Asia-Pacific Cervical Cancer Diagnostics Market Value, By Stage, 2021-2030 (US$ Million)

Table 41 Asia-Pacific Cervical Cancer Diagnostics Market Value, By End User, 2021-2030 (US$ Million)

Table 42 Asia-Pacific Cervical Cancer Diagnostics Market Value, By Country, 2021-2030 (US$ Million)

Table 43 Middle East & Africa Cervical Cancer Diagnostics Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 44 Middle East & Africa Cervical Cancer Diagnostics Market Value, By Test Type, 2021-2030 (US$ Million)

Table 45 Middle East & Africa Cervical Cancer Diagnostics Market Value, By Age Group, 2021-2030 (US$ Million)

Table 46 Middle East & Africa Cervical Cancer Diagnostics Market Value, By Stage, 2021-2030 (US$ Million)

Table 47 Middle East & Africa Cervical Cancer Diagnostics Market Value, By End User, 2021-2030 (US$ Million)

Table 48 F. Hoffmann-La Roche AG: Overview

Table 49 F. Hoffmann-La Roche AG: Product Portfolio

Table 50 F. Hoffmann-La Roche AG: Key Developments

Table 51 QIAGEN: Overview

Table 52 QIAGEN: Product Portfolio

Table 53 QIAGEN: Key Developments

Table 54 DaAnGene: Overview

Table 55 DaAnGene: Product Portfolio

Table 56 DaAnGene: Key Developments

Table 57 Molbio Diagnostics: Overview

Table 58 Molbio Diagnostics: Product Portfolio

Table 59 Molbio Diagnostics: Key Developments

Table 60 Cepheid: Overview

Table 61 Cepheid: Product Portfolio

Table 62 Cepheid: Key Developments

Table 63 Norgen Biotek Corp.: Overview

Table 64 Norgen Biotek Corp.: Product Portfolio

Table 65 Norgen Biotek Corp.: Key Developments

Table 66 Atila Diagnostics: Overview

Table 67 Atila Diagnostics: Product Portfolio

Table 68 Atila Diagnostics: Key Developments

Table 69 Abbott Laboratories: Overview

Table 70 Abbott Laboratories: Product Portfolio

Table 71 Abbott Laboratories: Key Developments

Table 72 Life Cell International: Overview

Table 73 Life Cell International: Product Portfolio

Table 74 Life Cell International: Key Developments

Table 75 Sansure Biotech: Overview

Table 76 Sansure Biotech: Product Portfolio

Table 77 Sansure Biotech: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 2 Global Cervical Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 3 Global Cervical Cancer Diagnostics Market Share, By Test Type, 2022 & 2030 (%)

Figure 4 Global Cervical Cancer Diagnostics Market Share, By Age Group, 2022 & 2030 (%)

Figure 5 Global Cervical Cancer Diagnostics Market Share, By Stage, 2022 & 2030 (%)

Figure 6 Global Cervical Cancer Diagnostics Market Share, By End User, 2022 & 2030 (%)

Figure 7 Global Cervical Cancer Diagnostics Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Cancer Type, 2022-2030 (%)

Figure 9 Squamous cell carcinoma Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 10 Adenocarcinoma Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 11 Small Cell Neuroendocrine Carcinoma Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 12 Others Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 13 Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Test Type, 2022-2030 (%)

Figure 14 Pap Smear test Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 15 Colposcopy test Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 16 HPV test Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 17 Imaging Tests Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 18 Cervical Biopsies Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 19 Biomarker testing Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 20 Others Test Type in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 21 Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 22 20-30 years Age Group in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 23 Above 30 years Age Group in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 24 Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Stage, 2022-2030 (%)

Figure 25 I Stage in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 26 II Stage in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 27 III Stage in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 28 IV Stage in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 29 Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 30 Hospitals and Clinics in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 31 Cancer Diagnostic Centers in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 32 Cancer Research Institutes in Global Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 33 Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 34 North America Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 35 Asia-Pacific Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 36 Europe Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 37 South America Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 38 Middle East and Africa Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 39 North America Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 40 North America Cervical Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 41 North America Cervical Cancer Diagnostics Market Share, By Test Type, 2022 & 2030 (%)

Figure 42 North America Cervical Cancer Diagnostics Market Share, By Age Group, 2022 & 2030 (%)

Figure 43 North America Cervical Cancer Diagnostics Market Share, By Stage, 2022 & 2030 (%)

Figure 44 North America Cervical Cancer Diagnostics Market Share, By End User, 2022 & 2030 (%)

Figure 45 North America Cervical Cancer Diagnostics Market Share, By Country, 2022 & 2030 (%)

Figure 46 South America Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 47 South America Cervical Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 48 South America Cervical Cancer Diagnostics Market Share, By Test Type, 2022 & 2030 (%)

Figure 49 South America Cervical Cancer Diagnostics Market Share, By Age Group, 2022 & 2030 (%)

Figure 50 South America Cervical Cancer Diagnostics Market Share, By Stage, 2022 & 2030 (%)

Figure 51 South America Cervical Cancer Diagnostics Market Share, By End User, 2022 & 2030 (%)

Figure 52 South America Cervical Cancer Diagnostics Market Share, By Country, 2022 & 2030 (%)

Figure 53 Europe Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 54 Europe Cervical Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 55 Europe Cervical Cancer Diagnostics Market Share, By Test Type, 2022 & 2030 (%)

Figure 56 Europe Cervical Cancer Diagnostics Market Share, By Age Group, 2022 & 2030 (%)

Figure 57 Europe Cervical Cancer Diagnostics Market Share, By Stage, 2022 & 2030 (%)

Figure 58 Europe Cervical Cancer Diagnostics Market Share, By End User, 2022 & 2030 (%)

Figure 59 Europe Cervical Cancer Diagnostics Market Share, By Country, 2022 & 2030 (%)

Figure 60 Asia-Pacific Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 61 Asia-Pacific Cervical Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 62 Asia-Pacific Cervical Cancer Diagnostics Market Share, By Test Type, 2022 & 2030 (%)

Figure 63 Asia-Pacific Cervical Cancer Diagnostics Market Share, By Age Group, 2022 & 2030 (%)

Figure 64 Asia-Pacific Cervical Cancer Diagnostics Market Share, By Stage, 2022 & 2030 (%)

Figure 65 Asia-Pacific Cervical Cancer Diagnostics Market Share, By End User, 2022 & 2030 (%)

Figure 66 Asia-Pacific Cervical Cancer Diagnostics Market Share, By Country, 2022 & 2030 (%)

Figure 67 Middle East & Africa Cervical Cancer Diagnostics Market Value, 2021-2030 (US$ Million)

Figure 68 Middle East & Africa Cervical Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 69 Middle East & Africa Cervical Cancer Diagnostics Market Share, By Test Type, 2022 & 2030 (%)

Figure 70 Middle East & Africa Cervical Cancer Diagnostics Market Share, By Age Group, 2022 & 2030 (%)

Figure 71 Middle East & Africa Cervical Cancer Diagnostics Market Share, By Stage, 2022 & 2030 (%)

Figure 72 Middle East & Africa Cervical Cancer Diagnostics Market Share, By End User, 2022 & 2030 (%)

Figure 73 F. Hoffmann-La Roche AG: Financials

Figure 74 QIAGEN: Financials

Figure 75 DaAnGene: Financials

Figure 76 Molbio Diagnostics: Financials

Figure 77 Cepheid: Financials

Figure 78 Norgen Biotek Corp.: Financials

Figure 79 Atila Diagnostics: Financials

Figure 80 Abbott Laboratories: Financials

Figure 81 Life Cell International: Financials

Figure 82 Sansure Biotech: Financials

세계 자궁경부암 진단 시장 – 2023-2030

Global Cervical Cancer Diagnostics Market - 2023-2030